Sébastian Desprez (Adaptimmune Therapeutics plc (Nasdaq: ADAP))

Desprez, Sébastian (Adaptimmune 201710– VP Communications + IR before ViiV Healthcare + GSK)

	Organisation	Adaptimmune Therapeutics plc (Nasdaq: ADAP)
	Group	Adaptimmune (Group)
	Product	public relations / investor relations / marcom (services)
	Product 2	TCR engineering technology (T-cell receptor engineering technology)

Record changed: 2022-07-18

Picture Berlin Partner Events Bionnale 2025 May HealthCapital 650x200px

More documents for Sébastian Desprez

[1] Adaptimmune Ltd.. (10/5/19). "Press Release: United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4". Philadeliphia, PA & Oxfordshire....
[2] Adaptimmune Ltd.. (9/30/19). "Press Release: Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO". Philadeliphia, PA & Oxfordshire....
[3] Adaptimmune Therapeutics plc. (7/22/19). "Press Release: Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center". Philadeliphia, PA & Oxfordshire....
[4] Adaptimmune Therapeutics plc. (7/18/19). "Press Release: Adaptimmune Starts the SURPASS Clinical Trial with Its First Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses". Philadeliphia, PA & Oxfordshire....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]